Alkor Bio Group, which now unites 12 companies, was founded in 1992 and is currently the largest biotechnology holding company in Northwestern Russia. Alkor Bio is well known in the market as one of the leading domestic manufacturers of reagents for enzyme immunoassay.
The main activities of Alkor Bio:
development, manufacture and marketing of enzyme immunoassay test kits and molecular genetic test kits
development of new cell technologies and their subsequent introduction into clinical practice
investments in highly scientific projects in the field of biotechnology
Alkor Bio Group is the most technologically advanced among the medical biotechnology companies of the Northwestern Federal District due to the introduction of ISO 13485:2003 (medical devices) and ISO 9001:2008 quality management standards.
The head company of the holding is Alkor Bio Company Ltd., a leader in hormonal and allergy diagnostics among domestic producers and agents. The company produces annually over 200,000 sets of reagents. These include tests for hormonal diagnostics, diagnostics of cancer, allergies, infectious diseases, kits and software for prenatal screening for Down syndrome, etc. (over 60 sets of reagents.) Diagnostic kits produced by Alkor Bio are registered in the Federal Service on Surveillance in Healthcare and Social Development of Russian Ministry of Health (Roszdravnadzor) and have EU – CE marking indicating high quality of products and their compliance with European standards.
Alkor Bio also provides a range of services: technical support, training, timely delivery and consulting support. Besides, Alkor Bio is the exclusive supplier to the Russian market of a modern automatic analyzer “Alisei”. This high-speed analyzer is able to significantly improve operational efficiency of the diagnostic laboratory.
The affiliated Vega Ltd. includes five research laboratories – laboratory developing ELISA test kits, allergy laboratory, molecular diagnostics laboratory, biochemical and hybridoma laboratories. Vega Ltd. specializes in development of diagnostic kits, all the laboratories are equipped with modern high-tech equipment.
Trans-Technologies Ltd. includes a stem cell bank and a research laboratory. The company Trans-Technologies is the only company in Northwestern Russia that performs clinical research in the field of cellular technologies. The work is conducted jointly with St. Petersburg’s leading medical institutions. Significant progress has been made in the following areas: medicine cardiology, traumatology, oncohematology, neurology and dentistry. Research team developed a range of biologically active new generation wound dressing.
Diagnostic Centers “Alkor Bio” Ltd. provides laboratory diagnostic services in St. Petersburg. Besides, the laboratory complex Diagnostic Centers “Alkor Bio” is a clinical testing ground for diagnostic products manufactured by Alkor Bio.
Gene Ltd. develops and manufactures the PCR test systems for diagnosis of hereditary diseases. The company′s product catalog includes sets of reagents for the identification of genetic susceptibility to osteoporosis, cardiovascular system diseases, mental disorders, as well as a DNA chip for the diagnosis of severe genetic disease cystic fibrosis.
Alkor Finance Ltd. provides financial and consulting services to the companies incorporated into Alkor Bio Group.
Alkor Bio Group launched web-based journal "Commercial Biotechnology", aimed to promote the development and commercialization of biotechnology in Russia.
The companies of Alkor Bio Group have eleven patents, including those in the area of diagnosis of cancer, diagnosis of hepatitis C virus, methods for treating severe fractures, periodontitis and mental retardation using stem cells. Alkor Bio Group is Russia′s only non-state company which invests its own funds in the basic research in the field of human stem cell biology and development of methods for their use in therapy of brain, heart and circulatory system damages, cancer and pathology of the nervous system.
Currently, Alkor Bio Group is developing some 40 innovation projects in key areas of its activities. Total investment in these projects amounts to 20 million dollars. Almost all the scientific developments that underlie the projects are world novelties, with patent applications having been filed. The most part of Alkor Bio innovation projects is financed from the group’s own funds.
Alkor Bio Group is a multiple winner of the award of the Government of St. Petersburg for the best innovation project to be implemented within the framework of the cluster; two-time winner of the contest "Best exporter of St. Petersburg", winner of the contest for the best innovation projects in science and higher education in St. Petersburg in the category "Best science and innovation idea"; member of the federal exhibition "Best projects of Russia", member of the national program "Oncology"; multiple leader of the independent ranking of the most successful small and medium enterprises of St. Petersburg " Business Gazelle" in the category "The most high-tech company" and "The most innovative company of St. Petersburg."
Since 2011, Alkor Bio Group has been a member of the Technology Platform "Medicine of the Future" and the Scientific-Technical Council “Molecular and cellular targets for diagnosis and therapy” functioning on the base of this platform." TP "Medicine of the Future" was the first officially established technology platform in the Russian Federation. The platform "Medicine of the Future" operates under the patronage of the Ministry of Economic Development and the Ministry of Education and Science.